Key takeaway
What This Development Means
Interested participants are required to register by the 17 March, 2024, with the event operating on a first-come, first-served basis due to limited space. Use Foresight.
Source basis: https://health.ec.europa.eu/events/public-hearing-scheer-guidelines-presence-phthalates-certain-medical-devices-2024-04-11_en
The European Commission's dedication to public health safety takes a significant step forward with the announcement of a public hearing by the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER). Scheduled for the 11 April, 2024, this event aims to address the presence of phthalates in certain medical devices, focusing on updating guidelines related to their benefit-risk assessment.
Public Consultation And Hearing Details
The hearing is part of a broader public consultation process, open from 27 March to 28 April 2024, allowing for a comprehensive collection of comments, suggestions, and scientific inputs on the guidelines. This initiative showcases the Commission's commitment to evidence-based policymaking and stakeholder engagement in health and safety regulations.
The Significance Of Phthalates
Phthalates, known for their flexibility-enhancing properties, are widely used in various products, including medical devices. Given their potential health risks, such as carcinogenic and endocrine-disrupting effects, their use in medical settings is being re-evaluated, leading to the need for updated safety guidelines.
Scientific Discussion And Participation
The Brussels hearing will serve as a platform for scientists and technical experts to discuss scientific evidence concerning phthalates in medical devices. Emphasizing a scientific approach, the Commission has stated that the event will focus solely on scientific matters, explicitly prohibiting public relations or lobbying efforts.
Registration And Attendance
Interested participants are required to register by the 17 March, 2024, with the event operating on a first-come, first-served basis due to limited space. The Commission has advised against making travel or accommodation arrangements until participation is confirmed, noting that it will not cover any related expenses.
Conclusion And Further Information
This public hearing represents a key moment in the European Commission's efforts to ensure the highest health and safety standards for its citizens. It underscores the importance of scientific inquiry and public involvement in addressing emerging health risks. The final program and list of participants will be made available on the Scientific Committees' website, offering further insight into the event's objectives and significance.
For those invested in the regulatory landscape of medical devices and public health policy, the SCHEER public hearing on 11 April 2024, is a pivotal event marking the European Commission's proactive stance on health and safety concerns.
Related Articles
EU Launches Public Consultation On Phthalates In Medical Devices
Stakeholders are encouraged to provide feedback on the preliminary guidelines by submitting written comments.
ECHA Hazard Classification Consultation Spotlights Silver Chloride And Reproductive Toxicity Risks
ECHA’s latest hazard classification consultation places silver chloride and several reproductive toxicants under scrutiny. With wide-ranging hazard classes proposed, the outcome could reshape compliance obligations, supply chains and risk management practices across multiple industries before the June 2026 deadline.
EU REACH Restrictions Face Scrutiny Over CMRs In Childcare Products And Lead Ammunition
The EU REACH Committee will debate major restrictions on CMRs in childcare products and lead ammunition, while NGOs criticise delays in wider chemical regulation. The proposals could tighten compliance requirements across European supply chains.
